Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Sarah E. Daadi"'
6
Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation
Autor: Rie von Eyben, Ranjana H. Advani, Karen S. Corbelli, Sarah E. Daadi, Richard T. Hoppe, Saul A. Rosenberg, Christopher R. Weil, Yushen Qian
Publikováno v: Leukemialymphoma. 61(10)
Management of stage I-II unfavorable risk Hodgkin lymphoma (HL) strives to reduce toxicity while maintaining tumor control. Compared to ABVD or BEACOPP, Stanford V chemotherapy contains less doxorubicin and bleomycin. We report long-term outcomes of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfaed10a46adfc41f76d853567f56a3d
https://pubmed.ncbi.nlm.nih.gov/32476541
Zobrazit plný text záznamu
7
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study
Autor: Manisha Desai, Sarah E. Daadi, Vandana Sundaram, Richard T. Hoppe, Douglas J. Wood, Ryan C. Lynch, Solomon Henry, Ranjana H. Advani
Publikováno v: JCO Oncol Pract
PURPOSE: Classic Hodgkin lymphoma is highly curable with contemporary therapy. Although the limited role of surveillance imaging to detect early relapse for patients in complete remission at the end of therapy is well established, there is a paucity
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66f4198d67a2621934c7c73e95cc578
https://europepmc.org/articles/PMC7489479/
Zobrazit plný text záznamu
8
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Autor: Christopher D. Carey, Courtney Connelly, Christine Pak, Daphne de Jong, Margaret A. Shipp, Richard T. Hoppe, Bjoern Chapuy, Scott J. Rodig, Margaretha G.M. Roemer, Ranjana H. Advani, Azra H. Ligon, Donna Neuberg, Robert A. Redd, Geraldine S. Pinkus, Yasodha Natkunam, Sarah E. Daadi
Publikováno v: Roemer, M G M, Advani, R H, Redd, R A, Pinkus, G S, Natkunam, Y, Ligon, A H, Connelly, C F, Pak, C J, Carey, C D, Daadi, S E, Chapuy, B, de Jong, D, Hoppe, R T, Neuberg, D S, Shipp, M A & Rodig, S J 2016, ' Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status ', Cancer Immunology Research, vol. 4, no. 11, pp. 910-916 . https://doi.org/10.1158/2326-6066.CIR-16-0201
Cancer Immunology Research, 4(11), 910-916. American Association for Cancer Research Inc.
In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligands is attr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2159ae75bb260e090e5ae9579883e6e
https://pubmed.ncbi.nlm.nih.gov/27737878
Zobrazit plný text záznamu
9
No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission
Autor: Manisha Desai, Ryan C. Lynch, Saul A. Rosenberg, Karen S. Corbelli, Solomon Henry, Vandana Sundaram, Richard T. Hoppe, Douglas Wood, Ranjana H. Advani, Sarah E. Daadi
Publikováno v: Blood. 132:615-615
Background: Classic Hodgkin lymphoma (CHL) is currently highly curable. Surveillance guidelines have been extrapolated largely from an era where sophisticated staging techniques were lacking, radiotherapy alone was the mainstay of therapy, and cure r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07776f41724e8f53f1506ce76283e96b
https://doi.org/10.1182/blood-2018-99-113156
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje